Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hepatology
•
Alcohol-associated Liver Disease
How has the move away from a strict 6 month period of sobriety impacted your patient selection criteria for transplant of patients with alcohol associated liver disease?
Related Questions
How do you balance infection risk versus therapeutic benefit of steroid tapers when treating patients with alcohol related hepatitis?
How do you approach a conversation with a patient with a markedly positive PETH (>200 ug/L) who is insistent that they do not consume any alcohol?
With the growth of non-alcoholic beverages (e.g., NA beer, liquor, etc), how do you approach a patient's consumption of these products in the setting of alcohol related liver disease?
In what clinical scenario would larsucosterol be considered as therapy in alcohol related hepatitis?
What role is there for use of ELF in patients with active alcohol use disorder for which Fibroscan is not able to give a reliable assessment of fibrosis due to ongoing active alcohol use?
How do you incorporate addiction medicine and counseling into your treatment plan for patients with alcohol associated liver disease?
What factors into your choice to use craving-related medications (e.g., baclofen, naltrexone, acamprosate, etc.) in the management of alcohol use disorder?
How do you utilize the Sustained Alcohol Use Post-Liver Transplant (SALT) score on surveillance for alcohol use for patients after liver transplant?
Is there a role for use of GLP-1/GIP receptor agonists in the management of substance use disorders, whether or not they meet other inclusion criteria for their use?
When would you consider quantification of hepatitis B surface antigen as part of the treatment decision making process?
